

March 4, 2021

Sumitomo Dainippon Pharma Co., Ltd.

**Sumitomo Dainippon Pharma Earns Recognition for the First Time
in the Health & Productivity Management Stock Selection**

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura) has been named for the first time as one of the enterprises selected in the Health & Productivity Management Stock Selection. The company has also been recognized, for the fifth consecutive year, as one of the enterprises in the Certified Health & Productivity Management Outstanding Organizations Recognition Program (Large Enterprise Category (White 500)).

The Health & Productivity Stock Selection program is organized jointly by the Ministry of Economy, Trade and Industry (METI) and the Tokyo Stock Exchange (TSE) to recognize outstanding listed enterprises which focus on and strategically carry out efforts with regard to their employees' health from a management perspective.

Certified Health & Productivity Management Outstanding Organizations are selected and recognized by the Nippon Kenko Kaigi for their outstanding health and productivity management practices undertaken in collaboration with insurers. METI recognizes the top 500 large enterprises as the "White 500", which are to be selected from the large enterprises certified under the Certified Health & Productivity Management Organizations Recognition Program (Large Enterprise Category) based on the results of the Survey on Health and Productivity Management.

Sumitomo Dainippon Pharma has set forth its corporate mission "to broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide." In order to help achieve this corporate mission, we believe that it is essential to create a work environment that enable all employees actively engage in their own duties while maintaining both mental and physical health. To this end, we have been proactively engaged in health and safety management initiatives, building on a wide range of relevant systems.

In October 2017, we drew up the Declaration of Health Innovation to actively involve ourselves in the promotion of the health of our employees and members of their families to help them lead fulfilling lives both during and outside of work. Under the Declaration of Health Innovation, we are promoting specific initiatives in collaboration with the Sumitomo Dainippon Pharma Health Insurance Society, focusing on the following four goals: (1) reducing the smoking rate; (2) preventing further deterioration of individuals' health; (3) maintaining mental health; and (4) having all insured individuals undergo specific medical checkups.

It was cited that, in the selection process of the 2021 Health & Productivity Management Stock Selection, our company had been highly evaluated for the following main points: steady progress in systematic efforts aiming at having zero smokers and the improved cancer screening rate among women in response to our active encouragement.

We at Sumitomo Dainippon Pharma will remain committed to assisting all employees and their family members in their activities to live healthy and fulfilling lives so that we can thereby contribute to the betterment of healthcare and fuller the lives of people worldwide.



For details on our “Health, Safety, and Welfare of Employees” initiatives, please visit our website.

https://www.ds-pharma.com/csr/with_employee/workplace_environment.html

Contact

Corporate Communications

Sumitomo Dainippon Pharma Co., Ltd.

TEL: + 81-6-6203-1407 (Osaka); + 81-3-5159-3300 (Tokyo)